Epstein–Barr Virus (HHV-4) Infections Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Epstein–Barr Virus (HHV-4) Infections
Epstein–Barr Virus (HHV-4) Infections Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Epstein–Barr Virus (HHV-4) Infections Infection pipeline products.
DISEASE OVERVIEW
Epstein–Barr Virus (HHV-4) Infections infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.
Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
REPORT DESCRIPTION
The Epstein–Barr Virus (HHV-4) Infections Infection pipeline guide presents complete overview of drugs currently being developed for Epstein–Barr Virus (HHV-4) Infections Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Epstein–Barr Virus (HHV-4) Infections Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Epstein–Barr Virus (HHV-4) Infections Infection pipeline candidates is included.
Major companies participating in therapeutic development of Epstein–Barr Virus (HHV-4) Infections Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Epstein–Barr Virus (HHV-4) Infections Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Epstein–Barr Virus (HHV-4) Infections Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Epstein–Barr Virus (HHV-4) Infections Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Epstein–Barr Virus (HHV-4) Infections infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.
Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
REPORT DESCRIPTION
The Epstein–Barr Virus (HHV-4) Infections Infection pipeline guide presents complete overview of drugs currently being developed for Epstein–Barr Virus (HHV-4) Infections Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Epstein–Barr Virus (HHV-4) Infections Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Epstein–Barr Virus (HHV-4) Infections Infection pipeline candidates is included.
Major companies participating in therapeutic development of Epstein–Barr Virus (HHV-4) Infections Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Epstein–Barr Virus (HHV-4) Infections Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Epstein–Barr Virus (HHV-4) Infections Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Epstein–Barr Virus (HHV-4) Infections Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE REPORT INCLUDES
- Panorama of Epstein–Barr Virus (HHV-4) Infections Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Epstein–Barr Virus (HHV-4) Infections Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Epstein–Barr Virus (HHV-4) Infections Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Epstein–Barr Virus (HHV-4) Infections Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Epstein–Barr Virus (HHV-4) Infections Infection pipeline therapeutics
- Get clear understanding of the entire Epstein–Barr Virus (HHV-4) Infections Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Epstein–Barr Virus (HHV-4) Infections Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Epstein–Barr Virus (HHV-4) Infections Infection Pipeline include
Number of Companies with Epstein–Barr Virus (HHV-4) Infections Infection projects in pre-clinical Development
Number of Companies with Epstein–Barr Virus (HHV-4) Infections Infection projects in Clinical Development
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Americas
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Europe
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Asia Pacific
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Agents in Clinical Development stage
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Epstein–Barr Virus (HHV-4) Infections Infection Pipeline agents
II. INSIGHTS INTO EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE
1. Disease Overview
Introduction to Epstein–Barr Virus (HHV-4) Infections Infection
Symptoms and Causes of Epstein–Barr Virus (HHV-4) Infections Infection
Treatment or Prevention Options for Epstein–Barr Virus (HHV-4) Infections Infection
Other Details
2. Phase wise Pipeline Compounds
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Pre- Clinical/Discovery stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Phase 1 stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Phase 2 stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Phase 3 stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Pre-Registration stage Drugs
3. Company wise Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Compounds
4. Epstein–Barr Virus (HHV-4) Infections Infection Pipeline by Mechanism of Action
III. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE COMPOUND DETAILS
ATA188
ATA190
Atara tab-cel
SAVINE technology for Epstein Barr virus
Small Molecules for Epstein-Barr Virus Infections
EBV-CTL
VT-EBV
CMD-003
EBViNT
GEN-003
EBV vaccine
EBV-related nasopharyngeal carcinoma
GPR183
Small Molecule for EBV-associated Lymphomas
SV-638
TT10
EBV-TIE
VRx-3996
Viralym-M
Small Molecule for EBV
CDK 4/6/9 inhibitors for EBV
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE COMPANY BRIEFS
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
BioDiem Ltd
Biotron Ltd
bluebird bio Inc
Boryung ViGenCell Inc
Cell Medica Ltd
Eutilex Co Ltd
Genocea Biosciences Inc
Helmholtz Zentrum M?nchen
Lion TCR Pte Ltd
Omeros Corp
Phoenicia Biosciences Inc
Sapvax
Tessa Therapeutics Pte Ltd
Vectorite Biomedical Inc
Viracta Therapeutics Inc
ViraCyte LLC
Vironika LLC
ViroStatics srl
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Epstein–Barr Virus (HHV-4) Infections Infection Pipeline include
Number of Companies with Epstein–Barr Virus (HHV-4) Infections Infection projects in pre-clinical Development
Number of Companies with Epstein–Barr Virus (HHV-4) Infections Infection projects in Clinical Development
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Americas
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Europe
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Asia Pacific
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Agents in Clinical Development stage
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Epstein–Barr Virus (HHV-4) Infections Infection Pipeline agents
II. INSIGHTS INTO EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE
1. Disease Overview
Introduction to Epstein–Barr Virus (HHV-4) Infections Infection
Symptoms and Causes of Epstein–Barr Virus (HHV-4) Infections Infection
Treatment or Prevention Options for Epstein–Barr Virus (HHV-4) Infections Infection
Other Details
2. Phase wise Pipeline Compounds
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Pre- Clinical/Discovery stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Phase 1 stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Phase 2 stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Phase 3 stage Drugs
Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Pre-Registration stage Drugs
3. Company wise Epstein–Barr Virus (HHV-4) Infections Infection Pipeline Compounds
4. Epstein–Barr Virus (HHV-4) Infections Infection Pipeline by Mechanism of Action
III. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE COMPOUND DETAILS
ATA188
ATA190
Atara tab-cel
SAVINE technology for Epstein Barr virus
Small Molecules for Epstein-Barr Virus Infections
EBV-CTL
VT-EBV
CMD-003
EBViNT
GEN-003
EBV vaccine
EBV-related nasopharyngeal carcinoma
GPR183
Small Molecule for EBV-associated Lymphomas
SV-638
TT10
EBV-TIE
VRx-3996
Viralym-M
Small Molecule for EBV
CDK 4/6/9 inhibitors for EBV
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE COMPANY BRIEFS
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
BioDiem Ltd
Biotron Ltd
bluebird bio Inc
Boryung ViGenCell Inc
Cell Medica Ltd
Eutilex Co Ltd
Genocea Biosciences Inc
Helmholtz Zentrum M?nchen
Lion TCR Pte Ltd
Omeros Corp
Phoenicia Biosciences Inc
Sapvax
Tessa Therapeutics Pte Ltd
Vectorite Biomedical Inc
Viracta Therapeutics Inc
ViraCyte LLC
Vironika LLC
ViroStatics srl
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
